Targeted Therapy for Metastatic Renal Cell Carcinoma

Area of Science:

• Oncology
• Nephrology
• Pharmacology

Background:

• Metastatic renal cell carcinoma (mRCC) prognosis has improved due to targeted therapy advancements over the last decade.
• Three main classes of targeted therapies have emerged: multi-targeted tyrosine kinase inhibitors (TKI), mammalian target of rapamycin (mTOR) inhibitors, and anti-VEGF monoclonal antibodies.

Purpose of the Study:

• To critically review current evidence on targeted therapy for mRCC patients.
• To analyze treatment recommendations based on risk stratification and prior treatment history.

Main Methods:

• Review of clinical trials evaluating targeted therapies in mRCC.
• Stratification of patients based on Memorial Sloan Kettering Cancer Center (MSKCC) risk model.
• Analysis of treatment recommendations for first-line and subsequent settings.

Main Results:

• First-line treatments for favorable/intermediate-risk clear-cell mRCC include sunitinib, pazopanib, or bevacizumab plus IFN-α.
• For patients progressing after cytokine therapy, sorafenib or axitinib are options.
• For TKI-refractory clear-cell mRCC, sorafenib, everolimus, temsirolimus, or axitinib may be used, though optimal sequencing is unclear.
• Temsirolimus is recommended for poor-risk clear-cell and non-clear cell mRCC based on Phase III trials.

Conclusions:

• Targeted therapies offer significant advancements in mRCC treatment.
• Treatment selection is guided by risk stratification and prior therapy, but optimal sequencing requires further investigation.
• Ongoing clinical trials for novel agents may redefine future mRCC treatment standards.